This clinical trial is focused on studying the effects of stopping certain medications in people with chronic hepatitis B infection. Chronic hepatitis B is a long-term infection of the liver caused by the hepatitis B virus. The study will involve medications that are commonly used to treat this condition, including Vemlidy (which contains the active substance tenofovir alafenamide), Tenofovir disoproxil (found in products like Viread and Tenofovir disoproxil Viatris), and Entecavir (found in products like Baraclude and Entecavir Krka). These medications are taken as film-coated tablets.

The purpose of the study is to understand how stopping these medications affects the virus in people who have been on treatment for a long time. The study will look at how the virus behaves after the treatment is stopped, particularly in people who are HBeAg negative, which means they do not have a specific protein in their blood that is often present in active hepatitis B infections. Participants will be monitored for changes in their health and the virus over a period of time after they stop taking the medication.

During the study, participants will take either the medication or a placebo, and their health will be closely monitored. The study will last for several months, and researchers will check the levels of the virus in the blood and other health markers to see how the virus responds to the treatment being stopped. The goal is to see if the virus remains under control without the medication and to understand the role of ethnicity in these outcomes. This information could help improve future treatment plans for people with chronic hepatitis B.